Facebooktwitterlinkedin

Asepsis announces the launch of Colistimethate Sodium for Injection in India

Asepsis Pharmaceuticals™ , Inc. announces the product launch of Colistimethate Sodium for Injection in India.  This is the first of several product launches Asepsis has planned for India.  Colistimethate sodium is used to treat Pseudomonas aeruginosa infections in cystic fibrosis patients, however has recently been indicated and received worldwide notice for use in treating multidrug-resistant infection and is one of the last-resort antibiotics for multidrug-resistant Pseudomonas aeruginosa, Acinetobacter and New Delhi metallo-β-lactamase multidrug-resistant Enterobacteriaceae, also known as the New Deli Superbug.

  • Share Us
  • Facebooktwitterlinkedin

    USA

    Asepsis Pharmaceuticals Inc.
    1584 Independence Blvd.
    Sarasota, FL 34234
    United States
    Tel: +1 888-608-8884
    Fax: +1 888-608-8885
    info@asepsispharma.com

    Mexico

    Asepsis Pharma SA de CV
    La Polar #6 DEPTO1 Colonial Del.
    Gustavo A Madero C.P. 07800
    Mexico D.F.
    Tel: +52 (55) 5750-3516
    Fax: +52 (55) 2789-5706
    info@asepsispharma.com

    India

    Asepsis Pharmaceuticals Pvt. Ltd.
    226, Patel Center, Sainath
    Road Malad West
    Mumbai
    Tel: +91 22 2844 2942
    Fax: +91 22 6645 9822
    info@asepsispharma.com

    China

    Asepsis Pharmaceuticals Ltd.
    12 F Merrit Industrial
    Center Kowloon,
    Hong Kong
    Tel: +852 9018 2393
    Fax: +852 3010 1873
    info@asepsispharma.com